Drug treatment of orthostatic hypotension and vasovagal syncope

Heart Disease

Volumn 5, Issue 1, 2003, Pages 49-64

  Frishman, William H ^a,c   Azer, Victor ^a   Sica, Domenic ^b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CLONIDINE; DISOPYRAMIDE; DOPAMINE BETA MONOOXYGENASE; EPHEDRINE; ERGOTAMINE; FLUDROCORTISONE; FLUOXETINE; HYDRALAZINE; IBUPROFEN; INDOMETACIN; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PINDOLOL; RECOMBINANT ERYTHROPOIETIN; SOMATOSTATIN; THEOPHYLLINE; VASOACTIVE AGENT; VERAPAMIL; WARFARIN; YOHIMBINE;

AGING; ANXIETY; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE MONITORING; BRAIN CIRCULATION; CLINICAL FEATURE; DIARRHEA; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DYSAUTONOMIA; ENZYME DEFICIENCY; HEADACHE; HEART HEMODYNAMICS; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC MONITORING; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; IRON DEFICIENCY; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PRESSORECEPTOR REFLEX; PRURITUS; QUALITY OF LIFE; REFLEX; SHY DRAGER SYNDROME; SIDE EFFECT; SKIN TINGLING; SODIUM RESTRICTION; SYNCOPE; URINARY HESITANCY; URINE RETENTION; VASOCONSTRICTION; VENOUS RETURN;

EID: 0037268944     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HDX.0000050416.53995.43     Document Type: Article

References (161)

1. Freeman R, Miyawaki E. The treatment of autonomic dysfunction. J Clin Neurophysiol 1993;10:61-82.
2. Warner EA, Wallach PM, Adelman HM, et al. Dizziness in primary care patients. J Intern Med 1992;7:454-463.
3. Thomas DJ, Bannister R. Preservation of autoregulation of cerebral blood flow in autonomic failure. J Neurol Sci 1980;44:205-212.
4. Dobkin BH. Orthostatic hypotension as a risk factor for symptomatic occlusive cerebrovascular disease. Neurology 1989;39:30-34.
5. Kapoor WN. Syncope. N Engl J Med 2000;343:1856-1862.
6. Mosqueda-Garcia R, Furlan R, Tank J, et al. The elusive pathophysiology of neurally mediated syncope. Circulation 2000;102:2898-2906.
7. Robertson D, Wade D, Robertson RM. Postprandial alterations in cardiovascular hemodynamics in autonomic dysfunctional states. Am J Cardiol 1981;48:1048-1052.
8. Robertson D, Davis TJ. Recent advances in the treatment of orthostatic hypotension. Neurology 1995;45:S26-S32.
9. Hollister A. Orthostatic hypotension: causes, evaluation, and management. Western J Med 1992;157:652-657.
10. Herr RD, Zun L, Mathews JJ. A directed approach to the dizzy patient. Ann Emerg Med 1989;18:664-672.
11. Ooi WH, Barrett S, Hossain M, et al. Patterns of orthostatic blood pressure change, and their clinical correlates in a frail, elderly population. JAMA 1997;277:1299-1304.
12. Maurer MS, Karmally W, Rivadencira H, et al. Upright posture and postprandial hypotension in elderly persons. Ann Intern Med 2000;133:533-536.
13. Lipsitz LA. Orthostatic hypotension in the elderly. New Engl J Med 1989;321:952-957.
14. Robbins AS, Rubinstein LZ. Postural hypotension in the elderly. J Am Geriatr Soc 1984;32:769-7774.
15. Bonema JD, Maddens ME. Syncope in elderly patients: why their risk is higher. Postgrad Med 1992;91:129-132, 135-136, 142-144.
16. Sloane PD, Blazer D, George LK. Dizziness in a community elderly population. J Am Geriatr Soc 1989;37:101-108.
17. Sloane PD, Coeytaux RR, Beck RS, et al. Dizziness: state of the science. Ann Intern Med 2001;134:823-832.
18. Sewall H. The clinical relations of gravity, posture and circulation. Am J Med Sci 1916;151:491-505.
19. Guyton AC, Hall JE (eds). Pocket Companion of the Textbook of Medical Physiology, 10th ed. Philadelphia: WB Saunders, 2001.
20. Jacob G, Shannon JR, Costa F, et al. Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. Circulation 1999;99:1706-1712.
21. Mathias CJ. Orthostatic hypotension: Causes, mechanisms and influencing factors. Neurology 1995;45:S6-S11.
22. Robertson D. Treatment of cardiovascular disorders: orthostatic hypotension. In: Melmon KL, Morelli HF, Hoffman BB, et al (eds). Clinical Pharmacology, Basics Principles of Therapeutics, 3rd ed. New York, Macmillan Press, 1992:84-103.
23. Zeigler MG. Postural hypotension: initial treatment and combined therapy. In Messerli F (ed). Cardiovascular Drug Therapy, 2nd ed. Philadelphia: WB Saunders, 1996:94-101.
24. Montastruc JL, Laborie I, Bagheri H, et al. Drug-induced orthostatic hypotension. A five-year experience in a regional pharmacovigilance centre in France. Clin Drug Invest 1997;14:61-65.
25. Robertson D, Goldberg MR, Onrot J, et al. Isolated failure of autonomic noradrenergic neurotransmission: Evidence of impaired beta-hydroxylation of dopamine. N Engl J Med 1986;314:1494-1497.
26. Man in't Veld AJ, Boomsma F, Moleman P, et al. Congenital dopamine-betahydroxylase deficiency: a novel orthostatic syndrome. Lancet 1987;1:183-188.
27. Hines S, Houston M, Robertson D. The clinical spectrum of autonomic dysfunction. Am J Med 1981;70:1091-1096.
28. Robertson D. Contraindication to the use of ocular phenylephrine in idiopathic orthostatic hypotension. Am J Opthalmol 1979;87:819-822.
29. Manolis AS, Linzer M, Salem D, et al. Syncope: current diagnosis, evaluation and management. Ann Intern Med 1990;112:850-863.
30. Blomqvist CG. Orthostatic hypotension. Hypertension 1986;8:722-732.
31. Gaffney FA, Bastian BC, Lane LB, et al. Abnormal cardiovascular regulation in the mitral valve prolapse syndrome. Am J Cardiol 1983;52:316-320.
32. Low PA, Tonette EL, Textor S, et al. Postural tachycardia syndrome (POTS). Neurology 1995;4:S19-S25.
33. Goldstein DS, Holmes C, Frank SM, et al. Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes. Circulation 2002;106:2358-2365.
34. Narkiewicz K, Somers VK. Chronic orthostatic intolerance. Part of a spectrum of dysfunction in orthostatic cardiovascular homeostasis? Circulation 1998;98:2105-2107.
35. Jacob G, Costa F, Shannon JR, et al. The neuropathic postural tachycardia syndrome. New Engl J Med 2000;343:1008-1014.
36. Ali YS, Daamen N, Jacob G, et al. Orthostatic intolerance: a disorder of young women. Obstet Gynecol Surv 2000;55:251-259.
37. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds). Williams Textbook of Endocrinology, 10th ed. Philadelphia: WB Saunders, 1985:1363-1379.
38. Kaufmann H. Primary autonomic failure: three clinical presentations of one disease [editorial]? Ann Intern Med 2000;133:382-383.
39. Bradbury S, Eggleston C. Postural hypotension - a report of three cases. Am Heart J 1925;1:73-86.
40. Schatz IJ. Orthostatic hypotension: II. Clinical diagnosis, testing, and treatment. Arch Intern Med 1984;144:1037-1041.
41. Biaggioni I, Robertson D, Krantz S, et al. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 1994;121:181-186.
42. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol 1960;2:511-527.
43. Polinsky RJ, McRae A, Baser SM, et al. Antibody in the CSF of patients with multiple system atrophy react specifically with rat locus ceruleus. J Neurol Sci 1991;106:96-104.
44. Mann S, Airman DG, Raftery EB, Bannister R. Circadian variation of blood pressure in autonomic failure. Circulation 1983;8:477-483.
45. Terazaki H, Ando Y, Yamashita T, et al. Visceral orthostatic hypotension in patients with severe autonomic dysfunction. J Auton Nerv Syst 1998;68:101-108.
46. Kaufmann H. Primary autonomic failure: three clinical presentations of one disease? Ann Intern Med 2000;133:382-384.
47. Mathias CJ. Autonomic disorders and their recognition. New Engl J Med 1997;336:721-724.
48. Colosimo C, Albanese A, Hughes AJ, et al. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 1995;52:294-298.
49. Koller WC (ed). Handbook of Parkinson's Disease. New York: Marcel Dekker, 1992.
50. Goldstein DS, Holmes C, Li ST, et al. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000;133:338-347.
51. Schatz IJ. Orthostatic Hypotension. Philadelphia: Davis, 1986.
52. Rilcy CM, Day RL, Greeley DM, ct al. Central autonomic dysfunction with defective lacrimation: report of five cases. Pediatrics 1949;3:468-478.
53. Anderson SL, Coli R, Daly IW, et al. Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet 2001;68:753-758.
54. Kolata G. Parents take charge, putting gene hunt onto the fast track. The New York Times, July 16, 1996.
55. Bar-On E, Floman Y, Sagiv S, Katz K, et al. Orthopaedic manifestations of familial dysautonomia. A review of one hundred and thirty-six patients. J Bone Joint Surg 2000;82-A:1563-1570.
56. Kaufman S. Coenzymes and hydroxylases: ascorbatc and dopamine-beta-hydroxylase. Pharmacol Rev 1986;18:61-69.
57. Goldstein M. Inhibition of norepinephrine biosynthesis at the dopamine-bctahydroxylase stage. Pharmacol Rev 1966;18:77-82.
58. Axelrod J. Dopamine-beta-hydroxylase: regulation of its synthesis and release from nerve terminals. Pharmacol Rev 1972;24:233-243.
59. Robertson D, Goldberg MR, Onrot J, et al. Isolated failure of autonomic noradrenergic neurotransmission. New Engl J Med 1986;314:1494-1497.
60. Man in't Veld AJ, Boosma F, van den Meiracker AH, et al. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet 1987;2:172-175.
61. Man in't Veld AJ, Boomsma F, Moleman P, et al. Congenital dopamine-betahydroxylase deficiency: a novel orthostatic syndrome. Lancet 1987;1:183-188.
62. Biaggioni I, Goldstein DS, Atkinson T, et al. Dopamine-beta-hydroxylase deficiency in humans. Neurology 1990;40:370-373.
63. Bennett T, Gardiner SM. Cardiovascular pathophysiology in diabetes mellitus: a reappraisal. In: Bannister R (ed). Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System, 2nd ed. Oxford: Oxford University Press, 1988:654-666.
64. Porcellati F, Fanelli C, Bottini P, et al. Mechanism of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy. Diabetes 1993;42:1055-1064.
65. Sasaki E, Goda K, Nagata K, et al. Acarbose improved severe postprandial hypotension in a patient with diabetes mellitus. J Diabetes Complications 2001;15:158-161.
66. Stavachevsky I, Rachmani R, Levi Z, et al. Effect of enalapril and nifedipine on orthostatic hypotension in older hypertensive patients. J Am Geriatr Soc 2000;48:807-810.
67. Cohen JA, Laudenslager M. Autonomic nervous system involvement in patients with human immunodeficiency virus infection. Neurology 1989;39:1111-1112.
68. Goldstein DS, Holmes CS, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002;58:1247-1255.
69. Savage DD, Corwin L, McGee DL, et al. Epidemiologic features of isolated syncope: The Framingham Study. Stroke 1985;16:626-629.
70. Gendelman HE, Linzer M, Gabelman M, et al. Syncope in a general hospital patient population. New York State Med 1983;83:1161-1165.
71. Day SC, Cook EF, Funkenstein H, et al. Evaluation and outcome of emergency room patients with transient loss of consciousness. Am J Med 1982;73:15-23.
72. Farrehi PM, Santinga JT, Eagle KA. Syncope: diagnosis of cardiac and noncardiac causes. Geriatrics 1995;50:24-30.
73. Mathias CJ, Deguchi K, Schatz I. Observations on recurrent syncope and presyncopc in 641 patients. Lancet 2001;357:348- 353.
74. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002;347:878-885.
75. Kaufmann H. Neurally mediated syncope: pathogenesis, diagnosis and treatment. Neurology 1995;45:S12-S18.
76. Shen WK, Hammill S, Monger T, et al. Adenosine: potential modulator for vasovagal syncope. J Am Coll Cardiol 1996;28:146-154.
77. Saadjian AY, Levy S, Franceschi F, et al. Role of endogenous adenosine as a modulator of syncope induced during tilt testing. Circulation 2002;106:569-574.
78. Brignole M, Gaggioli G, Menozzi C, et al. Clinical features of adenosine sensitive syncope and tilt induced vasovagal syncope. Heart 2000;83:24-28.
79. Dan D, Hoag JB, Ellenbogen KA, et al. Cerebral blood flow velocity declines before arterial pressure in patients with orthostatic vasovagal presyncope. J Am Coll Cardiol 2002;39:1039-1045.
80. Lagi A, Cencetti S, Corsoni V, et al. Cerebral vasoconstriction in vasovagal syncope: Any link with symptoms? Circulation 2001;104:2694-2698.
81. Theopistou A, Gatzoulis K, Economou E, et al. Biochemical changes involved in the mechanism ofvasovagal syncope. Am J Cardiol 2001;88:376-381.
82. Benditt D, Ferguson D, Grubb B, et al. Tilt table testing for assessing syncope. J Am Coll Cardiol 1996;28:263-275.
83. Boh-oka S, Ohmori H, Kawabe T, et al. Neurally mediated syncope and cardiac β-adrenergic receptor function. Journal of Cardiovascular Pharmacology 2001;38(Suppl 1):S75-S79.
84. Fenton AM, Hammill SC, Rea RF, et al. Vasovagal syncope. Ann Intern Med 2000;133:714-725.
85. Almquist A, Goldenberg IF, Millstein S, et al. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. New Engl J Med 1989;320:346-351.
86. Raviele A, Menozzi C, Brignole M, et al. Value of head-up tilt testing potentiated with sublingual nitroglycerin to assess the origin of unexplained syncope. Am J Cardiol 1995;76:267-272.
87. Waxman MB, Yao L, Cameron DA, et al. Isoproterenol induction of vasodepressor-type reaction in vasodepressor prone persons. Am J Cardiol 1989;63:58-65.
88. Schnipper JL, Kapoor WN. Diagnostic evaluation and management of patients with syncope. Med Clin North Am 2001;85:423-456.
89. Theodorakis GN, Markianos M, Zarvalis E, et al. Provocation of neurocardiogenic syncope by clomipramine administration during the head-up tilt test in vasovagal syndrome. J Am Coll Cardiol 2000;36:174-178.
90. Mitral S, Stein KM, Markowitz SM, et al. Induction of neurally mediated syncope with adenosine. Circulation 1999;99:1318-1324.
91. Raviele A, Giada F, Brignole M, et al. Comparison of diagnostic accuracy of sublingual nitroglycerin test and low-dose isoproterenol test in patients with unexplained syncope. Am J Cardiol 2000;85:1194-1198.
92. Raviele A, Gasparini G, DiPede F, et al. Nitroglycerin infusion during upright tilt: a new test for the diagnosis of vasovagal syncope. Am Heart J 1994;127:103-111.
93. Zeng C, Zhu Z, Hu W, et al. Value of sublingual isosorbide dinitrate before isopro-terenol tilt rest for diagnosis of neurally mediated syncope. Am J Cardiol 1999;83:1059-1063.
94. Lurie KG, Durton J, Mangatt R, et al. Evaluation of edrophonium as a provocative agent for vasovagal syncope during head-up tilt table testing. Am J Cardiol 1993;72:1286-1290.
95. Nino J, Villar JC, Tahvanainen KUO, et al. Vasovagal susceptibility to nitrate or isoproterenol head-up tilt. Am J Cardiol 2001;88:1326-1330.
96. Linzer M, Yang EH, Estes NA III, et al. Diagnosing syncope. Part 2: unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med. 1997;127:76-86.
97. Sarasin FP, Louis-Simonet M, Carballo D, et al. Prospective evaluation of patients with syncope: a population based study. Am J Med 2001;111:177-184.
98. Grubb BP, Kosinski DJ. Syncope resulting from autonomic insufficiency syndromes associated with orthostatic intolerance. Med Clin North Am 2001;85:457-472.
99. Kapoor WN. Current evaluation and management of syncope. Circulation 2002;106:1606-1609.
100. Brignole M, Alboni P, Benditt D, et al. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001;22:1256-1306.
101. Ward C, Kenny RA. Reproducibility of orthostatic hypotension in symptomatic elderly. Am J Med 1996;100:418-422.
102. Taylor AA. Autonomic control of cardiovascular function: clinical evaluation in health and disease. J Clin Pharmacol 1994;34:363-374.
103. Krahn AD, Klein GJ, Norris C, et al. The etiology of syncope in patients with negative tilt table and electrophysiological testing. Circulation 1995;92:1819-1824.
104. Jordan J. New trends in the treatment of orthostatic hypotension. Curr Hypertens Rep 2001;3:216-226.
105. Mathias CJ, Kimber JR. Postural hypotension: causes, clinical features, investigation, and management. Annu Rev Med 1999;50:317-336.
106. Kochar MS. Management of postural hypotension. Curr Hypertens Rep 2000;2:457-462.
107. Robertson D. Therapy of orthostatic hypotension. In: Singh BN, Dzau V, Vanhoutte PM, Woosley RL (eds). Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994:1015-1023.
108. Onrot J, Goldberg MR, Biaggioni I, et al. Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. New Engl J Med 1985;313:549-554.
109. Robertson D, Wade D, Workman R, et al. Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 1981;67:1111-1117.
110. van Lieshout JJ, ten Harkel AD, Wieling W. Physical manoeuvres for combatting orthostatic dizziness in antonomic failure. Lancet 1992;339:897-898.
111. Mtinangi BL, Hainsworth R. Increased orthostatic tolerance following modcrate exercise training in patients with unexplained syncope. Heart 1998;80:596-600.
112. Kredier CTP, Dijk NV, Linzer M, et al. Management of vasovagal syncope, controlling or aborting faints by leg crossing and muscle tensing. Circulation 2002;106:1684-1689.
113. MacLean AR, Allen BV. Orthostatic hypotension and orthostatic tachycardia. Treatment with the "head-up" bed. JAMA 1940;115:2162-2167.
114. Jordan J, Shannon JR, Black BK, et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation 2000;101:504-509.
115. Seager LH. Pressor action of fluorohydrocortisone in orthostatic hypotension. Tufts Folia Medica 1963;9:56.
116. Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. New Engl J Med 1979;301:68-75.
117. Mitsky VP, Workman RJ, Nicholson WE, et al. A sensitive radioimmunoassay for fludrocortisone in human plasma. Steroids 1994;59:555-558.
118. Lim PO, Farquharson CA, Shiels P, et al. Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension 2001;37:856-861.
119. Vagaonescu TD, Saadia D, Tuhrim S, et al. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet 2000;355:725-726.
120. 1-adrenergic antagonist in chronic orthostatic intolerance. Circulation 2002;106:2946-2954.
121. Fishman WH, Shevell T. Drug therapy oforthostatic hypotension and vasovagal syncope. In Firshman WH, Sonnenbick EH (eds). Cardiovascular Pharmaco Therapeutics. New York: McGraw Hill, 1997:1231-1246.
122. Biaggioni I, Onrot J, Stewart CK, et al. The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA 1987;258:236-239.
123. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. New Engl J Med 2000;343:1826-1832.
124. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277:1046-1051.
125. Lathers CM, Charles JB. Orthostatic hypotension in patients, bedrest subjects and astronauts. J Clin Pharmacol 1994;34:403-417.
126. Low PA. Update on the evaluation, pathogenesis, and management of neurogenic orthostatic hypotension. Neurology 1995;45:S4-S5.
127. Piwinski SE, Jankovic J, McElligott MA. A comparison of post-space flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha-agonistmidodrine for these conditions. J Clin Pharmacol 1994;34:466-471.
128. Gilden JL. Midodrine in neurogenic orrhostatic hypotension. A new treatment. Int Angiol 1993;12:125-131.
129. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthosratic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med 1993;95:38-48.
130. Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orrhostaric hypotension. Am J Med 1995;99:604-610.
131. Oldenburg O, Mitchell A, Numberger J, et al. Ambulatory norepinephrine treatment of severe autonomic orthostafic hypotension. J Am Coll Cardiol 2001;37:219-223.
132. Onrot J, Goldberg MR, Biaggioni I, et al. Oral yohimbine in human autonomic failure. Neurology 1987;37:215-220.
133. Biaggioni I, Robertson RM, Robertson D. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol 1994;34:418-423.
134. Jordan J, Shannon JR, Biaggioni I, et al. Contrasting actions of pressor agents in severe autonomic failure. Am J Med 1998;105:116-124.
135. Brahmbhatt R, Baggaley P, Hockings B. Normalization of blood pressure in a patient with severe orthostatic hypotension and supine hypertension using clonidine. Hypertension 2001;37:E24.
136. Victor RG, Talman WT. Comparative effects of clonidine and dihydroergotamine on venomotor tone and orthostatic tolerance in patients with severe hypoadrenergic orthostatic hypotension. Am J Med 2002;112:361-368.
137. Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. New Engl J Med 1993;329:611-615.
138. Robertson D, Krantz SB, Biaggioni I. The anemia of microgravity and recumbency: role of sympathetic neural control of erythropoietin production. Acta Astronautica 1994;33:137-141.
139. Davies IB, Bannister R, Hensby C, Sever PS. The pressor actions of noradrenaline and angiotension II in chronic autonomic failure treated with indomethacin. Br J Clin Pharmacol 1980;10:223-229.
140. Hoeldtke RD, Israel BC. Treatment of orthostatic hypotension with octreotide. J Clin Endocrinol Metab 1989;68:1051-1059.
141. Hoeldtke RD, Horvath GG, Bryner KD, et al. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab 1998;83:339-343.
142. Man in't Veld AJ, Schalekamp MADH. Pindolol acts as a beta-adrenoceptor agonist in orthostatic hypotension: therapeutic implications. BMJ 1981;283:561.
143. Sra JS. Can we assess the efficacy of therapy in neurocardiogenic syncope [editorial comment]? J Am Coll Cardiol 2001;37:560-561.
144. Garzoulis KA, Toutouzas PK. Neurocardiogenic syncope. Aetiology and management. Drugs 2001;61:1415-1423.
145. Abi Samra FM, Davison NM, Gardner RD. Treatment of vasodepressor syncope with beta blockers: preliminary observations. J Am Coll Cardiol 1991;17:217a.
146. Madrid AH, Ortega J, Rebollo JG, et al. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol 2001;37:554-559.
147. Ammirati F, Colivicchi F, Santini M, for the Syncope Diagnosis and Treatment Study Investigators. Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope. A multicenter, randomized, controlled trial. Circulation 2001;104:52-57.
148. Flevari P, Livanis EG, Theodorakis GN, et al. Vasovagal syncope: A prospective, randomized crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. J Am Coll Cardiol 2002;40:499-505.
149. Kikushima S, Kobayashi Y, Nakagawa H, et al. Triggering mechanism for neurally mediated syncope induced by head-up tilt test. J Am Coll Cardiol 1999;33:350-357.
150. Cox MM, Perlman MR, Mayor MR, et al. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. J Am Coll Cardiol 1995;26:1293-1298.
151. Davies IB, Bannister R, Sever PS, et al. The pressor actions of noradrenaline, angiotensin II and saralasin in chronic autonomic failure, treated with fludrocortisone: Br J Clin Pharm 1979;8:253-260.
152. Samniah N, Sakaguchi S, Lurie KG, et al. Efficacy and safety of midodrine hydro-chloride in patients with refractory vasovagal syncope. Am J Cardiol 2001;88:80-83.
153. Mitro P, Trejbal D, Rybar R. Midodrine hydrochloride in the treatment of vasovagal syncope. PACE 1999;22:1620-1624.
154. Benditt DG, Fahy GJ, Lurie KG, et al. Pharmacotherapy of neurally mediated syncope. Circulation 1999;100:1242-1248.
155. Raviele A, Brignole M, Sutton R, et al for Vasovagal Syncope International Study (VASIS) Investigators. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope. A double-blind, randomized, placebo-controlled trial. Circulation 1999;99:1452-1457.
156. DiGirolamo E, Di Iorio C, Sabatini P, et al. Effects of paroxetine hydrochloride, a selective reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999;33:1227-1230.
157. Kaufman H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a double blind, randomized, crossover study. Ann Neurol 2002;52:342-345.
158. Nelson SD, Stanley M, Love CJ, et al. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med 1991;151:2425-2429.
159. Suleparuk S, Nies AS, Andros E, et al. The role of adenosine in promoting cardiac beta-adrenergic subsensitivity in aging humans. J Gerontol 1995;50: B128-B134.
160. Li SM, Fenton RA, Cutler BS, et al. Adenosine enhances nitric oxide production by vascular endothelial cells. Am J Physiol 1995;269:C519-C523.
161. Sra JS, Jazayeri MR, Avitall B. Comparison of cardiac pacing with drug therapy in the treatment of nearocardiogenic (vasovagal) syncope with bradycardia or asystole. New Engl J Med 1993;328:1085-1090.